000165283 001__ 165283
000165283 005__ 20240613105350.0
000165283 0247_ $$2doi$$a10.1016/j.schres.2022.08.025
000165283 0247_ $$2pmid$$apmid:36108465
000165283 0247_ $$2ISSN$$a0920-9964
000165283 0247_ $$2ISSN$$a1573-2509
000165283 0247_ $$2altmetric$$aaltmetric:135993657
000165283 037__ $$aDZNE-2022-01576
000165283 041__ $$aEnglish
000165283 082__ $$a610
000165283 1001_ $$aNorth, Hayley F$$b0
000165283 245__ $$aIncreased immune cell and altered microglia and neurogenesis transcripts in an Australian schizophrenia subgroup with elevated inflammation.
000165283 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2022
000165283 3367_ $$2DRIVER$$aarticle
000165283 3367_ $$2DataCite$$aOutput Types/Journal article
000165283 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1718268789_11706
000165283 3367_ $$2BibTeX$$aARTICLE
000165283 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000165283 3367_ $$00$$2EndNote$$aJournal Article
000165283 520__ $$aWe previously identified a subgroup of schizophrenia cases (~40 %) with heightened inflammation in the neurogenic subependymal zone (SEZ) (North et al., 2021b). This schizophrenia subgroup had changes indicating reduced microglial activity, increased peripheral immune cells, increased stem cell dormancy/quiescence and reduced neuronal precursor cells. The present follow-up study aimed to replicate and extend those novel findings in an independent post-mortem cohort of schizophrenia cases and controls from Australia. RNA was extracted from SEZ tissue from 20 controls and 22 schizophrenia cases from the New South Wales Brain Tissue Resource Centre, and gene expression analysis was performed. Cluster analysis of inflammation markers (IL1B, IL1R1, SERPINA3 and CXCL8) revealed a high-inflammation schizophrenia subgroup comprising 52 % of cases, which was a significantly greater proportion than the 17 % of high-inflammation controls. Consistent with our previous report (North et al., 2021b), those with high-inflammation and schizophrenia had unchanged mRNA expression of markers for steady-state and activated microglia (IBA1, HEXB, CD68), decreased expression of phagocytic microglia markers (P2RY12, P2RY13), but increased expression of markers for macrophages (CD163), monocytes (CD14), natural killer cells (FCGR3A), and the adhesion molecule ICAM1. Similarly, the high-inflammation schizophrenia subgroup emulated increased quiescent stem cell marker (GFAPD) and decreased neuronal progenitor (DLX6-AS1) and immature neuron marker (DCX) mRNA expression; but also revealed a novel increase in a marker of immature astrocytes (VIM). Replicating primary results in an independent cohort demonstrates that inflammatory subgroups in the SEZ in schizophrenia are reliable, robust and enhance understanding of neuropathological heterogeneity when studying schizophrenia.
000165283 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000165283 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000165283 650_7 $$2Other$$aGlia
000165283 650_7 $$2Other$$aMacrophages
000165283 650_7 $$2Other$$aPost-mortem
000165283 650_7 $$2Other$$aPsychosis
000165283 650_7 $$2Other$$aSubtype
000165283 650_7 $$2Other$$aSubventricular zone
000165283 650_2 $$2MeSH$$aHumans
000165283 650_2 $$2MeSH$$aMicroglia: metabolism
000165283 650_2 $$2MeSH$$aSchizophrenia: genetics
000165283 650_2 $$2MeSH$$aSchizophrenia: metabolism
000165283 650_2 $$2MeSH$$aFollow-Up Studies
000165283 650_2 $$2MeSH$$aAustralia
000165283 650_2 $$2MeSH$$aNeurogenesis: physiology
000165283 650_2 $$2MeSH$$aInflammation: metabolism
000165283 650_2 $$2MeSH$$aRNA, Messenger: metabolism
000165283 650_2 $$2MeSH$$aRNA
000165283 7001_ $$0P:(DE-2719)9001801$$aWeissleder, Christin$$b1$$udzne
000165283 7001_ $$aFullerton, Janice M$$b2
000165283 7001_ $$aWebster, Maree J$$b3
000165283 7001_ $$aWeickert, Cynthia Shannon$$b4
000165283 773__ $$0PERI:(DE-600)1500726-1$$a10.1016/j.schres.2022.08.025$$gVol. 248, p. 208 - 218$$p208 - 218$$tSchizophrenia research$$v248$$x0920-9964$$y2022
000165283 8564_ $$uhttps://pub.dzne.de/record/165283/files/DZNE-2022-01576_Restricted.pdf
000165283 8564_ $$uhttps://pub.dzne.de/record/165283/files/DZNE-2022-01576_Restricted.pdf?subformat=pdfa$$xpdfa
000165283 909CO $$ooai:pub.dzne.de:165283$$pVDB
000165283 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001801$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000165283 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000165283 9141_ $$y2022
000165283 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000165283 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000165283 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000165283 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-25$$wger
000165283 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCHIZOPHR RES : 2021$$d2022-11-25
000165283 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000165283 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000165283 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-25
000165283 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-25
000165283 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000165283 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2022-11-25
000165283 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000165283 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-25
000165283 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-25
000165283 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2022-11-25
000165283 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-25
000165283 9201_ $$0I:(DE-2719)1210011$$kAG Deleidi$$lMitochondria and Inflammation in Neurodegenerative Diseases$$x0
000165283 980__ $$ajournal
000165283 980__ $$aVDB
000165283 980__ $$aI:(DE-2719)1210011
000165283 980__ $$aUNRESTRICTED